NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights

Executive Summary

• NetraMark Holdings Inc. signed four separate contracts with a leading global pharmaceutical company to apply its NetraAI platform to multiple late‑stage clinical studies.
• The engagements will use AI analytics to identify explainable patient subpopulations, quantify variables influencing treatment and placebo responses, and improve overall trial variability insights.
• Contracts are executed under an existing master services agreement, representing a material expansion of the ongoing collaboration and a positive revenue opportunity for NetraMark.

Key Details

• Number of contracts: 4 distinct project agreements covering four pivotal clinical studies.
• Counterparty: Unnamed leading global pharmaceutical company (existing master services agreement).
• Scope of work:
• Apply NetraAI to clinical data from each study to uncover and characterize patient subpopulations that drive treatment response, placebo response, and trial variability.
• Identify explainable subpopulations; quantify clinical and demographic variables influencing outcomes.
• Technology used: NetraAI – a mathematically‑augmented AI system designed for interpretability and compliance with FDA expectations for explainable AI in drug development.
• Strategic significance: Expands the existing collaboration, demonstrating continued confidence from the sponsor and providing a new revenue stream tied to high‑value late‑stage trial analytics.
• CEO comment: “The signing of these four contracts represents a significant expansion of our ongoing collaboration with a leading pharmaceutical company.” – George Achilleos, CEO.

Notable Quotes

“Our NetraAI system seeks to generate explainable insights from complex, heterogeneous clinical datasets — enabling sponsors to better understand their patient populations and make more informed development decisions.” – George Achilleos, Chief Executive Officer

All boilerplate, forward‑looking statements, and company background sections have been omitted for brevity.